Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update [Yahoo! Finance]
Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
Company Research
Source: Yahoo! Finance
Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure acquisition proceeds $33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025 Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today reported its full year 2025 financial results and provided a fourth quarter business update. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed stated, “We are very proud of our significant clinical, strategic and financing accomplishments in 2025. We are now in an excellent financial and
Show less
Read more
Impact Snapshot
Event Time:
OBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OBIO alerts
High impacting Orchestra BioMed Holdings, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
OBIO
News
- Orchestra BioMed (OBIO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewswire
- Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRTGlobeNewswire
- Orchestra BioMed to Participate in Upcoming Institutional Investor ConferencesGlobeNewswire
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
OBIO
Sec Filings
- 3/12/26 - Form 10-K
- 2/27/26 - Form SCHEDULE
- 2/25/26 - Form SCHEDULE
- OBIO's page on the SEC website